NOD1 deficiency ameliorates the progression of diabetic retinopathy by modulating bone marrow–retina crosstalk
Abstract Background Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) plays a pivotal role in inducing metabolic inflammation in diabetes. Additionally, the NOD1 ligand disrupts the equilibrium of bone marrow-derived hematopoietic stem/progenitor cells, a process that has immense significance in the development of diabetic retinopathy (DR). We hypothesized that NOD1 depletion impedes the advancement of DR by resolving bone marrow dysfunction. Methods We generated NOD1−/−-Akita double-mutant mice and chimeric mice with hematopoietic-specific NOD1 depletion to study the role of NOD1 in the bone marrow–retina axis. Results Elevated circulating NOD1 activators were observed in Akita mice after 6 months of diabetes. NOD1 depletion partially restored diabetes-induced structural changes and retinal electrical responses in NOD1−/−-Akita mice. Loss of NOD1 significantly ameliorated the progression of diabetic retinal vascular degeneration, as determined by acellular capillary quantification. The preventive effect of NOD1 depletion on DR is linked to bone marrow phenotype alterations, including a restored HSC pool and a shift in hematopoiesis toward myelopoiesis. We also generated chimeric mice with hematopoietic-specific NOD1 ablation, and the results further indicated that NOD1 had a protective effect against DR. Mechanistically, loss of hematopoietic NOD1 resulted in reduced bone marrow-derived macrophage infiltration and decreased CXCL1 and CXCL2 secretion within the retina, subsequently leading to diminished neutrophil chemoattraction and NETosis. Conclusions The results of our study unveil, for the first time, the critical role of NOD1 as a trigger for a hematopoietic imbalance toward myelopoiesis and local retinal inflammation, culminating in DR progression. Targeting NOD1 in bone marrow may be a potential strategy for the prevention and treatment of DR..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Stem Cell Research & Therapy - 15(2024), 1, Seite 17 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jingwen Qiu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biochemistry |
|---|
| doi: |
10.1186/s13287-024-03654-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09217776X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09217776X | ||
| 003 | DE-627 | ||
| 005 | 20240414093816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13287-024-03654-y |2 doi | |
| 035 | |a (DE-627)DOAJ09217776X | ||
| 035 | |a (DE-599)DOAJ792c70f65dec4f9380d206ed4037e35b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 050 | 0 | |a QD415-436 | |
| 100 | 0 | |a Jingwen Qiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NOD1 deficiency ameliorates the progression of diabetic retinopathy by modulating bone marrow–retina crosstalk |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) plays a pivotal role in inducing metabolic inflammation in diabetes. Additionally, the NOD1 ligand disrupts the equilibrium of bone marrow-derived hematopoietic stem/progenitor cells, a process that has immense significance in the development of diabetic retinopathy (DR). We hypothesized that NOD1 depletion impedes the advancement of DR by resolving bone marrow dysfunction. Methods We generated NOD1−/−-Akita double-mutant mice and chimeric mice with hematopoietic-specific NOD1 depletion to study the role of NOD1 in the bone marrow–retina axis. Results Elevated circulating NOD1 activators were observed in Akita mice after 6 months of diabetes. NOD1 depletion partially restored diabetes-induced structural changes and retinal electrical responses in NOD1−/−-Akita mice. Loss of NOD1 significantly ameliorated the progression of diabetic retinal vascular degeneration, as determined by acellular capillary quantification. The preventive effect of NOD1 depletion on DR is linked to bone marrow phenotype alterations, including a restored HSC pool and a shift in hematopoiesis toward myelopoiesis. We also generated chimeric mice with hematopoietic-specific NOD1 ablation, and the results further indicated that NOD1 had a protective effect against DR. Mechanistically, loss of hematopoietic NOD1 resulted in reduced bone marrow-derived macrophage infiltration and decreased CXCL1 and CXCL2 secretion within the retina, subsequently leading to diminished neutrophil chemoattraction and NETosis. Conclusions The results of our study unveil, for the first time, the critical role of NOD1 as a trigger for a hematopoietic imbalance toward myelopoiesis and local retinal inflammation, culminating in DR progression. Targeting NOD1 in bone marrow may be a potential strategy for the prevention and treatment of DR. | ||
| 650 | 4 | |a Nucleotide-binding oligomerization domain-containing protein 1 | |
| 650 | 4 | |a Diabetic retinopathy | |
| 650 | 4 | |a Hematopoietic stem/progenitor cells | |
| 650 | 4 | |a Macrophage | |
| 650 | 4 | |a Inflammation | |
| 653 | 0 | |a Medicine (General) | |
| 653 | 0 | |a Biochemistry | |
| 700 | 0 | |a Jing Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Wenwen Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Ruan |e verfasserin |4 aut | |
| 700 | 0 | |a Jingning Mao |e verfasserin |4 aut | |
| 700 | 0 | |a Shue Li |e verfasserin |4 aut | |
| 700 | 0 | |a Xuan Tang |e verfasserin |4 aut | |
| 700 | 0 | |a Lei Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a Shengbing Li |e verfasserin |4 aut | |
| 700 | 0 | |a Ke Li |e verfasserin |4 aut | |
| 700 | 0 | |a Dongfang Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Yaqian Duan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Stem Cell Research & Therapy |d BMC, 2015 |g 15(2024), 1, Seite 17 |w (DE-627)DOAJ000049824 |x 17576512 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g pages:17 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13287-024-03654-y |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/792c70f65dec4f9380d206ed4037e35b |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13287-024-03654-y |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1757-6512 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |h 17 | ||